Chisom Ezuma-Ngwu: Crucial metabolic pathway in triple-negative breast cancer cells

Chisom Ezuma-Ngwu, Wellness Leader at Johns Hopkins Underrepresented in Medical Professions, shared a post on LinkedIn:

“I had the incredible opportunity to contribute to cutting-edge cancer research in Dr. Johannes Fahrmann’s lab at MD Anderson Cancer Center through the Cancer Prevention Research Training Program.

His team has uncovered a crucial metabolic pathway in triple-negative breast cancer (TNBC) cells.

By repurposing the FDA-approved drug Eliglustat, we can target this pathway and destroy the mitochondria within cancer cells.

This approach not only kills the cancer cells directly but also stimulates the body’s immune defenses against cancer.

My project specifically investigated whether combining Eliglustat with the PARP inhibitor Olaparib could enhance anti-cancer efficacy and amplify the immune response.

The results were promising, suggesting that this treatment strategy has the potential to improve health outcomes for women with triple-negative breast cancer.

I am grateful for the opportunity to share this journey with two wonderful trainees, Reece Collins and Nevon Din.

I am deeply grateful to my mentor, Johannes Fahrmann, yihui chen, and program director, Shine Chang for their mentorship and guidance.

Their support has ignited my passion for clinical research and inspired me to pursue a career as both a physician and a clinical researcher in cancer prevention.

I’m grateful for the chance to be part of a project that pushes the boundaries of cancer treatment and am excited to see where this research leads.”

Source: Chisom Ezuma-Ngwu/LinkedIn